Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	15.24	8.57	-68.57	22.81	-46.42	-89.76
Depreciation & Amortization	-	-	0	0.37	0.87	0.65
Stock-Based Compensation	3.88	4.33	7.79	7.93	9.12	9.43
Other Adjustments	1	1.64	1.04	6.28	6.61	2.47
Change in Receivables	24.24	27.09	44.81	-96.2	1.55	3.05
Changes in Accounts Payable	-1.55	-6.61	5.93	0.76	-0.48	-0.05
Changes in Accrued Expenses	-5.05	-12.15	11.17	-2.42	-5.38	2.11
Changes in Income Taxes Payable	-0.01	0.21	-0.21	0.39	-	-
Changes in Unearned Revenue	-29.81	-34.66	-26.63	29.01	21.89	10.64
Changes in Other Operating Activities	-1.29	-1.03	1.22	-1.91	4.51	-2.89
Operating Cash Flow	7.24	-12.62	-23.44	-33	-7.73	-64.35
Purchases of Investments	-	-	-	-	-26.97	-43.92
Proceeds from Sale of Investments	-	-	-	-	60.78	51.55
Other Investing Activities	-	-	-	-	-	0.04
Investing Cash Flow	-	-	-	-	33.81	7.67
Issuance of Common Stock	-	-	-	0.22	24.93	86.57
Net Common Stock Issued (Repurchased)	-	-	-	0.22	24.93	86.57
Other Financing Activities	-	-	-	-	-54.49	-2.52
Financing Cash Flow	-	-	-	0.22	-29.55	84.05
Net Cash Flow	7.24	-12.62	-23.44	-32.77	-3.48	27.38
Free Cash Flow	7.24	-12.62	-23.44	-33	-7.73	-64.35
FCF Margin	11.84%	-18.90%	-48.87%	-31.79%	-14.45%	-352.47%
Free Cash Flow Per Share	0.13	-0.21	-0.43	-0.62	-0.21	-2.08
Levered Free Cash Flow	-6.18	-45.15	-77.09	54.2	-25.01	-79.3
Unlevered Free Cash Flow	-23.96	-47.74	-81.89	49.87	-20.79	-77.51

Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q